programs from idea phase to phase II clinical proof-of-concept partnering and collaborating with more than 30 companies including virtual small biotechs, medium size to the largest pharma companies, covering the fields of both small molecules and large proteins (mAbs, ADC). They have completed due diligence of over 55 assets including technology platform, lead or optimized lead, preclinical and clinical drug candidates in various therapeutic areas.